Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances (Q38554422)

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Retracted: Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The onco-embryonic antigen ROR1 is expressed by a variety of human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Protein kinases--the major drug targets of the twenty-first century?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Novel and emerging targeted-based cancer therapy agents and methods

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Receptor tyrosine kinase signalling as a target for cancer intervention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Tinkering Outside the Kinase ATP Box: Allosteric (Type IV) and Bivalent (Type V) Inhibitors of Protein Kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Insights into Src kinase functions: structural comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Acquisition of a "Group A"-selective Src kinase inhibitor via a global targeting strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

An update on dual Src/Abl inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The JAK-STAT signaling pathway: input and output integration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

STATs in cancer inflammation and immunity: a leading role for STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Jaks and STATs: biological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

STAT activation in malignancies: roles in tumor progression and in the generation of antineoplastic effects of IFNs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

STAT signaling in different breast cancer sub-types

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

STAT signaling in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Jak-2 positive myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Ruxolitinib for the treatment of primary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Therapy for myeloproliferative neoplasms: when, which agent, and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Tofacitinib versus methotrexate in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Cancer-associated adipose tissue promotes breast cancer progression by paracrine oncostatin M and Jak/STAT3 signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Small molecular compounds in development for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Profile of pacritinib and its potential in the treatment of hematologic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Molecular pathways: BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase includ

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Allosteric interactions between the myristate- and ATP-site of the Abl kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The role of focal-adhesion kinase in cancer - a new therapeutic opportunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

FAK in cancer: mechanistic findings and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

FERM control of FAK function: implications for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Cellular characterization of a novel focal adhesion kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Tec family kinases in inflammation and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Itk inhibitors: a patent review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Advances in the design of ITK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Mantle cell lymphoma: observation to transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Bruton's TK inhibitors: structural insights and evolution of clinical candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Inhibitors of B-cell receptor signaling for patients with B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Ibrutinib (PCI-32765) in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The accessory factor Nef links HIV-1 to Tec/Btk kinases in an Src homology 3 domain-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Selective Itk inhibitors block T-cell activation and murine lung inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The Src, Syk, and Tec family kinases: distinct types of molecular switches

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Antigen receptor function in chronic lymphocytic leukemia B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Proteomic and genetic approaches identify Syk as an AML target

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Getting Syk: spleen tyrosine kinase as a therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Progressive loss of Syk and abnormal proliferation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group stud

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The clinical development of MEK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Resistance to BRAF-targeted therapy in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10-plex quantitative proteomics and phosphoproteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Selective and potent small-molecule inhibitors of PI3Ks

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

ZAP-70: an essential kinase in T-cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The antigen-major histocompatibility complex-T cell receptor interaction. A structural analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Chemical inhibitors when timing is critical: a pharmacological concept for the maturation of T cell contacts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

A sharp T-cell antigen receptor signaling threshold for T-cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Inhibition of ZAP-70 kinase activity via an analog-sensitive allele blocks T cell receptor and CD28 superagonist signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

Small-Molecule Inhibitors of the c-Fes Protein-Tyrosine Kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

The human c-Fes tyrosine kinase binds tubulin and microtubules through separate domains and promotes microtubule assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319

FES kinases are required for oncogenic FLT3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1068319